Akebia Therapeutics (AKBA) Stock Insights

AKBA price $0.70 +0.04 +5.44%

Ticker
AKBA
Price
$0.70
Change
+0.04 +5.44%
Market cap ?
$192.95M
P/E ?
-5.25
Forward P/E ?
12.11
Dividend yield ?
0.00%
Beta ?
0.23
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
69
Value
79
Quality
55
Growth
72

Stocklytics score rationale: value 79, quality 55, growth 72.

Financials

2016201720182019202020212022202320242025
1535000177984000207742000335001000294644000211650000292484000194623000160180000236196000

Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult…

Fair value

AKBA fair value $1.44. Price $0.70. Price is 52% below fair value.

Above fair value, but less expensive than usual. A smaller premium than on 90% of days in the past 5 years.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Calculated with a 10-year free-cash-flow discount. Starting free cash flow 13.60M. Growth 0.00%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 8.70% (beta 0.8). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 277.11M. Net debt 31.45M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the stock's own 10-year median P/E, kept between 8 and 40. Fewer than five years of history uses the sector's typical P/E. Fair value is the average of the cash-flow value and the earnings value when both exist. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.

Compare AKBA

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-09—-0.04—46.94M
2026-08-05-0.02-0.0449.13M48.85M
2026-05-07-0.03-0.0153.54M51.67M
2026-02-26-0.05-0.0357.62M46.09M
2025-11-100.00-0.0658.77M48.37M
2025-08-070.00-0.0262.47M47.89M
2025-05-080.03-0.0357.34M50.80M
2025-03-13-0.10-0.0546.50M37.41M
2024-11-07-0.10-0.0537.43M40.91M
2024-08-08-0.04-0.0643.65M49.45M
2024-05-09-0.09-0.0932.61M49.45M
2024-03-140.000.0056.20M55.39M
2023-11-08-0.08-0.0942.05M55.54M
2023-08-25-0.06-0.0356.38M59.10M
2023-05-08-0.14-0.1540.13M46.68M
2023-03-09-0.04-0.1455.18M47.40M
2022-11-03-0.28-0.1548.96M48.88M
2022-08-040.23-0.31126.76M53.03M
2022-05-09-0.35-0.2761.70M44.27M
2022-03-01-0.40-0.3359.60M51.77M
2021-11-04-0.34-0.3248.76M47.31M
2021-08-05-0.51-0.3052.91M39.29M
2021-05-10-0.45-0.3352.30M42.84M
2021-02-25-0.60-0.4356.70M51.16M
2020-11-05-0.42-0.2359.99M24.28M
2020-08-10-0.44-0.4690.14M35.21M
2020-05-05-0.47-0.6388.48M116.72M
2020-03-10-0.61-0.4569.56M41.38M
2019-11-12-0.28-0.3791.98M85.98M
2019-08-08-0.30-0.35100.80M65.83M
2019-05-09-0.44-0.4272.67M46.88M
2019-03-26-0.91-0.2759.85M62.45M
2018-11-08-0.46-0.7753.17M74.02M
2018-08-08-0.60-0.5248.79M41.48M
2018-05-09-0.48-0.5545.93M56.42M
2018-03-120.25-0.3587.32M126.84M
2017-11-08-0.49-0.7041.28M42.99M
2017-08-08-0.53-0.8228.52M46.78M
2017-05-09-1.15-0.5620.86M7.09M
2017-03-06-0.992.131.53M1.17M

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-08-06Butler John P.Buy350.00K$0.63220.50K
2026-08-06Butler John P.Sell350.00K$0.63220.50K
2026-06-29Ostrowski ErikSell56.02K$1.1162.18K
2026-06-17Wolf MylesBuy35.70K——
2026-06-17Wolf MylesBuy53.60K$1.0254.67K
2026-06-17Smith CynthiaBuy35.70K——
2026-06-17Smith CynthiaBuy53.60K$1.0254.67K
2026-06-17ROGERS MICHAEL WBuy35.70K——
2026-06-17ROGERS MICHAEL WBuy53.60K$1.0254.67K
2026-06-17FRIESON RONBuy35.70K——
2026-06-17FRIESON RONBuy53.60K$1.0254.67K
2026-06-17ZUMWALT LEANNE MBuy35.70K——
2026-06-17ZUMWALT LEANNE MBuy53.60K$1.0254.67K
2026-06-17ADAMS ADRIANBuy35.70K——
2026-06-17ADAMS ADRIANBuy53.60K$1.0254.67K
2026-04-01Vickers Philip J.Buy214.40K$1.41302.30K
2026-04-01Vickers Philip J.Other0——
2026-03-04Butler John P.Buy69.27K$1.2586.59K
2026-02-02Malabre Richard CSell36.14K$1.3950.24K
2026-02-02Malabre Richard CSell13.38K$1.3918.60K
2026-02-02Grund NicholasSell53.59K$1.3974.48K
2026-02-02Grund NicholasSell31.24K$1.3943.43K
2026-02-02Burke Steven KeithSell21.58K$1.3930.00K
2026-02-02Burke Steven KeithSell25.38K$1.3935.27K
2026-02-02Burke Steven KeithSell20.70K$1.3928.77K
2026-02-02Rucci Carolyn M.Sell16.85K$1.3923.42K
2026-02-02Rucci Carolyn M.Sell25.38K$1.3935.28K
2026-02-02Rucci Carolyn M.Sell27.54K$1.3938.29K
2026-02-02Ostrowski ErikSell34.95K$1.3948.58K
2026-02-02Butler John P.Sell46.66K$1.3964.86K
2026-02-02Butler John P.Buy175.25K$1.41247.10K
2026-02-02Butler John P.Sell96.06K$1.39133.53K
2026-02-02Butler John P.Sell83.69K$1.39116.33K
2026-02-02Butler John P.Sell114.89K$1.39159.70K
2026-01-30Grund NicholasBuy204.00K——
2026-01-30Grund NicholasBuy320.00K$1.41451.20K
2026-01-30Burke Steven KeithBuy204.00K——
2026-01-30Burke Steven KeithBuy320.00K$1.41451.20K
2026-01-30Rucci Carolyn M.Buy190.00K——
2026-01-30Rucci Carolyn M.Buy270.00K$1.41380.70K
2026-01-30Malabre Richard CBuy79.00K——
2026-01-30Malabre Richard CBuy119.00K$1.41167.79K
2026-01-30Ostrowski ErikBuy204.00K——
2026-01-30Ostrowski ErikBuy320.00K$1.41451.20K
2026-01-30Butler John P.Buy743.00K——
2026-01-30Butler John P.Buy1.11M$1.411.57M
2026-01-26Rucci Carolyn M.Other0——
2026-01-26Rucci Carolyn M.Other0——
2026-01-26Rucci Carolyn M.Other0——
2026-01-26Rucci Carolyn M.Other0——
2026-01-26Rucci Carolyn M.Other224.00K$1.68376.32K
2026-01-26Rucci Carolyn M.Other240.00K$2.24537.60K
2026-01-26Rucci Carolyn M.Other61.00K$2.88175.68K
2026-01-26Rucci Carolyn M.Other27.90K$2.1660.26K
2026-01-26Rucci Carolyn M.Other165.60K$0.63104.33K
2025-06-30Ostrowski ErikSell41.31K$3.67151.62K
2025-06-10ZUMWALT LEANNE MBuy35.70K——
2025-06-10ZUMWALT LEANNE MBuy53.60K$3.92210.11K
2025-06-10ADAMS ADRIANBuy35.70K——
2025-06-10ADAMS ADRIANBuy53.60K$3.92210.11K
2025-06-10Wolf MylesBuy35.70K——
2025-06-10Wolf MylesBuy53.60K$3.92210.11K
2025-06-10Smith CynthiaBuy35.70K——
2025-06-10Smith CynthiaBuy53.60K$3.92210.11K
2025-06-10ROGERS MICHAEL WBuy35.70K——
2025-06-10ROGERS MICHAEL WBuy53.60K$3.92210.11K
2025-06-10GILMAN STEVEN CBuy35.70K——
2025-06-10GILMAN STEVEN CBuy53.60K$3.92210.11K
2025-06-10FRIESON RONBuy35.70K——
2025-06-10FRIESON RONBuy53.60K$3.92210.11K
2025-06-09Malabre Richard CSell15.00K$1.6825.20K
2025-06-09Malabre Richard CBuy15.00K$1.6825.20K
2025-06-09Malabre Richard CSell15.00K$4.0160.15K
2025-06-04Malabre Richard CSell13.33K$3.5347.07K
2025-03-03Butler John P.Sell46.41K$1.8384.93K
2025-03-03Burke Steven KeithSell7.14K$1.8313.07K
2025-02-03Butler John P.Sell46.27K$2.1097.16K
2025-02-03Butler John P.Sell97.98K$2.10205.76K
2025-02-03Burke Steven KeithSell23.27K$2.1048.87K
2025-02-03Burke Steven KeithSell27.24K$2.1057.20K
2025-02-03Malabre Richard CSell30.20K$2.1063.42K
2025-02-03Grund NicholasSell55.62K$2.10116.80K
2025-01-31Butler John P.Buy701.00K——
2025-01-31Butler John P.Buy1.05M$2.242.36M
2025-01-31Butler John P.Buy350.50K——
2025-01-31Burke Steven KeithBuy194.90K——
2025-01-31Burke Steven KeithBuy292.30K$2.24654.75K
2025-01-31Malabre Richard CBuy85.00K——
2025-01-31Malabre Richard CBuy128.00K$2.24286.72K
2025-01-31Grund NicholasBuy194.90K——
2025-01-31Grund NicholasBuy292.30K$2.24654.75K
2025-01-31Ostrowski ErikBuy194.90K——
2025-01-31Ostrowski ErikBuy292.30K$2.24654.75K
2025-01-17FRIESON RONBuy20.10K$0.459.04K
2025-01-17FRIESON RONSell20.10K$0.459.04K
2024-06-28Ostrowski ErikBuy500.00K$1.02510.00K
2024-06-28Ostrowski ErikBuy350.00K——
2024-06-24Ostrowski ErikOther0——
2024-06-06Wolf MylesBuy30.00K——
2024-06-06Wolf MylesBuy45.00K$1.0748.15K

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 177, holders 0 vs prior quarter. Ownership 40.90%.

HolderSharesChangeChange %Value
BLACKROCK, INC.19.99M1.29M+6.92%22.78M
VANGUARD CAPITAL MANAGEMENT LLC11.32M155.43K+1.39%12.91M
AQR CAPITAL MANAGEMENT LLC9.15M7.36M+410.51%10.43M
GEODE CAPITAL MANAGEMENT, LLC6.73M275.05K+4.26%7.67M
STATE STREET CORP5.39M-6.22M-53.58%6.15M
JACOBS LEVY EQUITY MANAGEMENT, INC4.27M3.84M+894.49%4.87M
ACADIAN ASSET MANAGEMENT LLC4.00M2.63M+190.83%4.56M
GOLDMAN SACHS GROUP INC3.69M86.34K+2.40%4.21M
MILLENNIUM MANAGEMENT LLC3.20M811.89K+34.05%3.64M
VANGUARD PORTFOLIO MANAGEMENT LLC2.53M318.54K+14.38%2.89M
TWO SIGMA INVESTMENTS, LP2.44M1.14M+87.75%2.78M
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P.2.30M2.30MNew2.62M
CHARLES SCHWAB INVESTMENT MANAGEMENT INC2.30M284.86K+14.13%2.62M
NORTHERN TRUST CORP2.16M214.78K+11.04%2.46M
NANTAHALA CAPITAL MANAGEMENT, LLC2.00M00.00%2.28M
VANGUARD FIDUCIARY TRUST CO1.91M129.50K+7.28%2.18M
FMR LLC1.87M535.73K+40.12%2.13M
QUBE RESEARCH & TECHNOLOGIES LTD1.78M-615.51K-25.70%2.03M
CITADEL ADVISORS LLC1.72M1.56M+986.44%1.96M
UBS GROUP AG1.37M605.48K+78.69%1.57M
RENAISSANCE TECHNOLOGIES LLC1.22M-609.16K-33.23%1.40M
CITIGROUP INC1.12M-1.73M-60.60%1.28M
HENNION & WALSH ASSET MANAGEMENT, INC.839.73K206.48K+32.61%957.29K
MORGAN STANLEY701.54K120.21K+20.68%799.76K
INVESCO LTD.694.93K-25.21K-3.50%792.22K

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Akebia Therapeutics (AKBA) Stock Insights

AKBA$0.70+0.04 +5.44%

$192.95M

Market Cap

-5.25

P/E

12.11

Forward P/E

69

Score

Price History